RxDoctor Payments Data

Geoffrey Mire, MD

Family Medicine · Lafayette, LANPI 1114959442

Payments from drug & device makers

$13,041in general payments, 2019–2025

Across 851 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Novo Nordisk$1K
  • Amgen$978
  • Lilly USA, LLC$857
  • AbbVie$697
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$13,032100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,041 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$53,542
Medicare patients
227
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole189$135,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$129,965
EliquisApixaban418$124,441
NamzaricMemantine Hcl/Donepezil Hcl408$120,668
FarxigaDapagliflozin Propanediol312$97,342
EntrestoSacubitril/Valsartan177$62,955
MounjaroTirzepatide48$53,948
JanuviaSitagliptin Phosphate139$44,286
XareltoRivaroxaban149$42,955
ProliaDenosumab21$38,553
GemtesaVibegron122$29,960
BelsomraSuvorexant63$29,950
LinzessLinaclotide89$28,493
MyrbetriqMirabegron118$27,767
XifaxanRifaximin17$25,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$1,893$158,114276 claims
AbbVieNamzaric, Linzess, Lumigan$697$153,372513 claims
PfizerEliquis$278$124,441418 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$1,952$114,366364 claims
MerckJanuvia, Belsomra$297$74,236202 claims
NovartisEntresto$116$62,955177 claims
Johnson & JohnsonXarelto, Risperdal Consta$150$56,015169 claims
Lilly USA, LLCMounjaro$857$53,94848 claims
AmgenProlia$978$38,55321 claims
Astellas Pharma US IncMyrbetriq$335$27,767118 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$217$25,37017 claims
BayerKerendia$102$24,85976 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →